Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
Gynekologické malignity – stručný výber z prác prezentovaných na ASCO Annual Meeting 2017
29 septembra, 2020 8:30 pmÚvod Od 2. do 6. júna 2017 sa konal v Chicagu výročný kongres American Society of Clinical Oncology (ASCO), na ktorom sa stretlo viac...
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER
29 septembra, 2020 8:30 pmMeeting: 2017 ASCO Annual Meeting Track: Breast Cancer – Local/Regional/Adjuvant Abstract number: 501 Citation: J Clin Oncol...
A phase III trial of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2+ breast cancer: The TRAIN-2 study (BOOG 2012-03)
29 septembra, 2020 8:30 pmMeeting: 2017 ASCO Annual Meeting Track: Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy Abstract number: 507 Citation: J Clin Oncol 35,...
Phase II study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A
29 septembra, 2020 8:30 pmMeeting: 2017 ASCO Annual Meeting Track: Breast Cancer-Metastatic Abstract number: 1008 Citation: J Clin Oncol 35, 2017...
A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2-) metastatic breast cancer (mBC) (TREnd trial).
29 septembra, 2020 8:30 pmMeeting: 2017 ASCO Annual Meeting Track: Title:Breast Cancer-Metastatic Abstract number: 1002 Citation: J Clin Oncol 35, 2017...
APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC)
29 septembra, 2020 8:30 pmMeeting: 2017 ASCO Annual Meeting Track: Breast Cancer – Local/Regional/Adjuvant Abstract number: LBA500 Citation: J Clin Oncol...
Pertuzumab Reduced Risk of Invasive Disease–Free Survival Compared With Placebo in APHINITY
29 septembra, 2020 8:30 pmJune 5, 2017 Pertuzumab improved invasive disease–free survival (IDFS) in patients with HER2-positive, early-stage breast cancer when added to...
Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)
29 septembra, 2020 8:30 pmMeeting: 2017 ASCO Annual Meeting Track: Oral Abstract Session Breast Cancer – Metastatic Abstract number: LBA4 Citation:...
OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)
29 septembra, 2020 8:30 pmMeeting: 2017 ASCO Annual Meeting Track: Oral Abstract Session Breast Cancer – Metastatic Abstract number: LBA4 Citation:...
Olaparib Improves Outcomes in BRCA-Mutated Metastatic Breast Cancer
29 septembra, 2020 8:30 pmOlaparib tablet monotherapy yielded improved progression-free survival compared with standard-of-care chemotherapy among women with HER2-negative metastatic breast cancer and a...